<DOC>
	<DOCNO>NCT01523223</DOCNO>
	<brief_summary>This phase I trial study side effect best dose donor CD8+ memory T-cells treating patient hematolymphoid malignancy . Giving low dose chemotherapy donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-cancer effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect</brief_summary>
	<brief_title>Donor Peripheral Stem Cell Transplant Treating Patients With Hematolymphoid Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility purify allogeneic CD8+ memory T-cells suitable clinical application determine safety maximum tolerate dose ( MTD ) cell patient recurrent refractory hematolymphoid malignancy follow allogeneic hematopoietic cell transplant ( HCT ) . SECONDARY OBJECTIVES : I . To determine disease response , time disease progression , event-free survival , overall survival follow treatment allogeneic CD8+ memory T-cells . II . To assess donor specific chimerism designate time point treatment allogeneic CD8+ memory T-cells . OUTLINE : This dose-escalation study . Patients undergo CD8+ memory T-cell infusion 10-20 minute .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<criteria>Patients must undergo human leukocyte antigen ( HLA ) match ( sibling ) allogeneic HCT hematologic lymphoid malignancy chronic myelogenous leukemia ( CML ) recurrent persistent disease otherwise eligible donor leukocyte infusion CML patient persistent disease receive donor lymphocyte infusion least 1x10^8cells/kg eligible CD8+ memory T cell infusion Patients must evidence active graftversushost disease must stable immunosuppressive regimen without change drug dosage 4 week prior plan CD8+ memory T cell infusion Patients must active infection Patients must performance status &gt; 70 % Karnofsky scale Serum creatinine &lt; 2 mg/dl creatinine clearance &gt; 50 cc/min Bilirubin &lt; 3 mg/dl Transaminases &lt; 3 time upper limit normal Patients must negative antibody serology human immunodeficiency virus ( HIV1 2 ) hepatitis C virus negative test hepatitis B surface antigen DONOR : Donors must HLA match sibling Donors must 1875 year age , inclusive Donors must state general good health Donors must white blood cell count &gt; 3.5 x 10^9/liter DONOR : Platelets &gt; 150 x 10^9/liter Donors : Hematocrit &gt; 35 % Donors must capable undergoing leukapheresis Donors must seropositive HIV 1 2 , Hepatitis B surface antigen , Hepatitis B core antibody , Hepatitis C antibody , human Tlymphotropic virus ( HTLV ) antibody , cytomegalovirus ( CMV ) immunoglobulin ( Ig ) M , Rapid Plasma Reagin ( RPR ) ( Treponema ) Female donor must pregnant lactate Diagnosis CML except patient fail prior donor leukocyte infusion minimum cell dose 1x10^8 cells/kg Patients diagnosed second cancer ( except carcinoma situ cervix basal cell carcinoma skin ) currently active treat within three year prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>